These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 24156019)

  • 21. [AUO study AP 59/10: first-line therapy of castration-resistant prostate cancer].
    Rexer H
    Urologe A; 2011 Jun; 50(6):722-4. PubMed ID: 21584827
    [No Abstract]   [Full Text] [Related]  

  • 22. Potential use of custirsen to treat prostate cancer.
    Higano CS
    Onco Targets Ther; 2013; 6():785-97. PubMed ID: 23836992
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cotargeting Androgen Receptor and Clusterin Delays Castrate-Resistant Prostate Cancer Progression by Inhibiting Adaptive Stress Response and AR Stability.
    Matsumoto H; Yamamoto Y; Shiota M; Kuruma H; Beraldi E; Matsuyama H; Zoubeidi A; Gleave M
    Cancer Res; 2013 Aug; 73(16):5206-17. PubMed ID: 23786771
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The development of risk groups in men with metastatic castration-resistant prostate cancer based on risk factors for PSA decline and survival.
    Armstrong AJ; Tannock IF; de Wit R; George DJ; Eisenberger M; Halabi S
    Eur J Cancer; 2010 Feb; 46(3):517-25. PubMed ID: 20005697
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prior Endocrine Therapy Impact on Abiraterone Acetate Clinical Efficacy in Metastatic Castration-resistant Prostate Cancer: Post-hoc Analysis of Randomised Phase 3 Studies.
    Bellmunt J; Kheoh T; Yu MK; Smith MR; Small EJ; Mulders PF; Fizazi K; Rathkopf DE; Saad F; Scher HI; Taplin ME; Davis ID; Schrijvers D; Protheroe A; Molina A; De Porre P; Griffin TW; de Bono JS; Ryan CJ; Oudard S
    Eur Urol; 2016 May; 69(5):924-32. PubMed ID: 26508309
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Multiple Docetaxel Retreatments Without Prednisone for Metastatic Castration-Resistant Prostate Cancer in the Docetaxel-Only Era: Effects on PSA Kinetics and Survival.
    Maj-Hes A; Szarvas T; Sevcenco S; Kramer G
    Adv Ther; 2021 Jul; 38(7):3831-3841. PubMed ID: 34043207
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Serum Free Methylated Glutathione S-transferase 1 DNA Levels, Survival, and Response to Docetaxel in Metastatic, Castration-resistant Prostate Cancer: Post Hoc Analyses of Data from a Phase 3 Trial.
    Mahon KL; Qu W; Lin HM; Spielman C; Cain D; Jacobs C; Stockler MR; Higano CS; de Bono JS; Chi KN; Clark SJ; Horvath LG
    Eur Urol; 2019 Sep; 76(3):306-312. PubMed ID: 30466891
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Phase II trial of OGX-011 in combination with docetaxel in metastatic breast cancer.
    Chia S; Dent S; Ellard S; Ellis PM; Vandenberg T; Gelmon K; Powers J; Walsh W; Seymour L; Eisenhauer EA
    Clin Cancer Res; 2009 Jan; 15(2):708-13. PubMed ID: 19147778
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Current and emerging treatment modalities for metastatic castration-resistant prostate cancer.
    Bracarda S; Logothetis C; Sternberg CN; Oudard S
    BJU Int; 2011 Apr; 107 Suppl 2():13-20. PubMed ID: 21382150
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Evaluation of prostate-specific antigen declines for surrogacy in patients treated on SWOG 99-16.
    Petrylak DP; Ankerst DP; Jiang CS; Tangen CM; Hussain MH; Lara PN; Jones JA; Taplin ME; Burch PA; Kohli M; Benson MC; Small EJ; Raghavan D; Crawford ED
    J Natl Cancer Inst; 2006 Apr; 98(8):516-21. PubMed ID: 16622120
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pantoprazole Affecting Docetaxel Resistance Pathways via Autophagy (PANDORA): Phase II Trial of High Dose Pantoprazole (Autophagy Inhibitor) with Docetaxel in Metastatic Castration-Resistant Prostate Cancer (mCRPC).
    Hansen AR; Tannock IF; Templeton A; Chen E; Evans A; Knox J; Prawira A; Sridhar SS; Tan S; Vera-Badillo F; Wang L; Wouters BG; Joshua AM
    Oncologist; 2019 Sep; 24(9):1188-1194. PubMed ID: 30952818
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Optimizing the care of patients with advanced prostate cancer in the UK: current challenges and future opportunities.
    Payne H; Bahl A; Mason M; Troup J; De Bono J
    BJU Int; 2012 Sep; 110(5):658-67. PubMed ID: 22429837
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The effect of prior androgen synthesis inhibition on outcomes of subsequent therapy with docetaxel in patients with metastatic castrate-resistant prostate cancer: results from a retrospective analysis of a randomized phase 3 clinical trial (CALGB 90401) (Alliance).
    Aggarwal R; Halabi S; Kelly WK; George D; Mahoney JF; Millard F; Stadler WM; Morris MJ; Kantoff P; Monk JP; Carducci M; Small EJ;
    Cancer; 2013 Oct; 119(20):3636-43. PubMed ID: 23913744
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Anticancer Activity and Tolerance of Treatments Received Beyond Progression in Men Treated Upfront with Androgen Deprivation Therapy With or Without Docetaxel for Metastatic Castration-naïve Prostate Cancer in the GETUG-AFU 15 Phase 3 Trial.
    Lavaud P; Gravis G; Foulon S; Joly F; Oudard S; Priou F; Latorzeff I; Mourey L; Soulié M; Delva R; Krakowski I; Laguerre B; Théodore C; Ferrero JM; Beuzeboc P; Habibian M; Rolland F; Deplanque G; Pouessel D; Zanetta S; Berdah JF; Dauba J; Baciuchka M; Platini C; Linassier C; Tubiana-Mathieu N; Machiels JP; Kouri CE; Ravaud A; Suc E; Eymard JC; Hasbini A; Bousquet G; Culine S; Boher JM; Tergemina-Clain G; Legoupil C; Fizazi K
    Eur Urol; 2018 May; 73(5):696-703. PubMed ID: 29074061
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Updated prognostic model for predicting overall survival in first-line chemotherapy for patients with metastatic castration-resistant prostate cancer.
    Halabi S; Lin CY; Kelly WK; Fizazi KS; Moul JW; Kaplan EB; Morris MJ; Small EJ
    J Clin Oncol; 2014 Mar; 32(7):671-7. PubMed ID: 24449231
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A phase I study of OGX-011, a 2'-methoxyethyl phosphorothioate antisense to clusterin, in combination with docetaxel in patients with advanced cancer.
    Chi KN; Siu LL; Hirte H; Hotte SJ; Knox J; Kollmansberger C; Gleave M; Guns E; Powers J; Walsh W; Tu D; Eisenhauer E
    Clin Cancer Res; 2008 Feb; 14(3):833-9. PubMed ID: 18245546
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clusterin is a potential molecular predictor for ovarian cancer patient's survival: targeting clusterin improves response to paclitaxel.
    Hassan MK; Watari H; Han Y; Mitamura T; Hosaka M; Wang L; Tanaka S; Sakuragi N
    J Exp Clin Cancer Res; 2011 Dec; 30(1):113. PubMed ID: 22185350
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The effect of clinical trial participation versus non-participation on overall survival in men receiving first-line docetaxel-containing chemotherapy for metastatic castration-resistant prostate cancer.
    Goyal J; Nuhn P; Huang P; Tyagi P; Oh D; Carducci MA; Eisenberger MA; Antonarakis ES
    BJU Int; 2012 Dec; 110(11 Pt B):E575-82. PubMed ID: 22702837
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clusterin role in hepatocellular carcinoma patients treated with oxaliplatin.
    Wang X; Liu Y; Qin Q; Zheng T
    Biosci Rep; 2020 Feb; 40(2):. PubMed ID: 32039450
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Subsequent Chemotherapy and Treatment Patterns After Abiraterone Acetate in Patients with Metastatic Castration-resistant Prostate Cancer: Post Hoc Analysis of COU-AA-302.
    de Bono JS; Smith MR; Saad F; Rathkopf DE; Mulders PFA; Small EJ; Shore ND; Fizazi K; De Porre P; Kheoh T; Li J; Todd MB; Ryan CJ; Flaig TW
    Eur Urol; 2017 Apr; 71(4):656-664. PubMed ID: 27402060
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.